ReviewInternational journal of reproductive biomedicine2025
The role of tacrolimus in women with unexplained infertility: A narrative review.
Review in International journal of reproductive biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.Frontiers in immunology · 2026Review
- A review of immunosuppressive therapy in the context of uterine VCA and pregnancy.Frontiers in transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several autoimmune and immunological disorders can cause infertility. About 10-20% of infertility cases are related to fetal-maternal immune factors. The use of immunological treatments in women with infertility is an emerging strategy. Tacrolimus, a calcineurin inhibitor, has been shown in some studies to prevent fetal rejection and promote tolerance by inhibiting activated natural killer cells, natural killer T cells, and macrophages. In this review, we will evaluate the effects of tacrolimus on recurrent pregnancy loss and assisted reproductive technology failure. The search strategy for relevant articles was conducted in PubMed, Scopus, Google Scholar, and Web of Science databases using MeSH terms and keywords including Tacrolimus [mh], FK506, infertility [mh], abortion, spontaneous [mh], recurrent miscarriage, recurrent pregnancy loss, and recurrent implantation failure. We sought the most recent and reliable studies in the field of infertility. Tacrolimus is relatively safe and effective during pregnancy, with no major fetal-maternal complications. It is beneficial for with an elevated T helper-1/T helper-2 cell ratio. However, more studies should be designed to clarify the optimal dosage, treatment duration, and timing of initiation and cessation of tacrolimus to maximize its safety and efficacy during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.